key: cord-0701469-51jquk7e
authors: Simulundu, Edgar; Mweene, Aaron S.; Changula, Katendi; Monze, Mwaka; Chizema, Elizabeth; Mwaba, Peter; Takada, Ayato; Ippolito, Guiseppe; Kasolo, Francis; Zumla, Alimuddin; Bates, Matthew
title: Lujo viral hemorrhagic fever: considering diagnostic capacity and preparedness in the wake of recent Ebola and Zika virus outbreaks
date: 2016-09-05
journal: Rev Med Virol
DOI: 10.1002/rmv.1903
sha: 3a5f5151e75f16e9c2202a0c46a37547c6c4cc0e
doc_id: 701469
cord_uid: 51jquk7e

Lujo virus is a novel Old World arenavirus identified in Southern Africa in 2008 as the cause of a viral hemorrhagic fever (VHF) characterized by nosocomial transmission with a high case fatality rate of 80% (4/5 cases). Whereas this outbreak was limited, the unprecedented Ebola virus disease outbreak in West Africa, and recent Zika virus disease epidemic in the Americas, has brought into acute focus the need for preparedness to respond to rare but potentially highly pathogenic outbreaks of zoonotic or arthropod‐borne viral infections. A key determinant for effective control of a VHF outbreak is the time between primary infection and diagnosis of the index case. Here, we review the Lujo VHF outbreak of 2008 and discuss how preparatory measures with respect to developing diagnostic capacity might be effectively embedded into existing national disease control networks, such as those for human immunodeficiency virus, tuberculosis, and malaria.

Several outbreaks of VHF in humans are recorded each year globally. 3 With the glaring exception of the recent Ebola virus disease (EVD) epidemic in West Africa, VHF outbreaks are typically small, limited to less than 100 patients. The median number of patients for the 17 previous EVD outbreaks is 65. 4 Possibly due to the generally limited size of outbreaks, viruses associated with VHF have not been considered a priority for research funding. Consequently, existing diagnostics and therapeutics are limited, as is our understanding of the epidemiology, transmission, and animal reservoirs for some of these viruses.

However, the recent EVD epidemic in West Africa has shown that VHF outbreaks can occur where least expected (eg, West Africa, whereas most previous outbreaks were in Central Africa) 4, 5 and can rapidly spread out of control. As of February 28, 2016, the recent West African EVD outbreak had infected nearly 29 000 people, with more than 11 000 deaths. 6 Fragile and under-resourced health systems in these countries were sluggish in identifying the disease and were unable to respond rapidly and comprehensively enough to stop the spread of the disease. 7 The situation was further compounded by an initially slow and uncoordinated international response that has been widely condemned. [8] [9] [10] [11] The unprecedented magnitude of the West African EVD outbreak, along with the significant number of EVD survivors with persistent detectable virus in various body fluids (semen and ocular fluid) after recovering from the disease 12, 13 and/or complications 14 19, 20 As of 2016 the EVD epidemic is no longer out of control, but flare-ups continue: on March 17 Sierra Leone declared an end to a flare-up that started in January, yet on the very same day, a new patient was confirmed in Guinea leading to 5 deaths as of March 24, 2016 , prompting Liberia to close their shared border. This experience emphasizes the need to develop regional and national research networks to better understand the underlying causes of these outbreaks.

Lujo virus (LUJV) was discovered after an outbreak of VHF in Lusaka (Zambia) and Johannesburg (South Africa) in 2008 ( Figure 1) and was the first novel VHF-causing virus to be identified in Africa since the discovery of Ebola virus in 1976. 21 In Zambia and South Africa in 2008, a novel arenavirus (LUJV) infected 5 people, killing the index case and 3 health care workers. The index case was a white female aged 36 years who lived on a peri-urban farm close to Zambia's capital, Lusaka. On September 2, she experienced a sudden onset of severe headache, myalgia, fever, and sore throat and self-medicated with antipyretics and analgesics. 23, 24 On September 4 she travelled by air to South Africa to attend a wedding on September 6, returning to Zambia on September 7 (day 5 of her illness), when she reported diarrhea and vomiting 24 (reports diarrhea and vomiting on day 2). Her condition continued to worsen such that on day 7 of her illness she visited a private clinic in Lusaka complaining of severe chest pains, fever, rash, and sore throat for which she was given an assortment of medications (including antiemetic, antipyretic, analgesic, and broad spectrum antibiotics). The next 2 days, her condition rapidly degenerated as she experienced severe myalgias, facial swelling with central nervous system symptoms such as confusion and seizures.

She was hospitalized on day 9 and evacuated the following day by air ambulance to a private hospital in Johannesburg, South Africa. On physical examination, the patient exhibited edema of the face and neck, rash, and acute respiratory distress syndrome, but no hemorrhage was observed. Clinical laboratory tests showed that she had elevated liver transaminases, thrombocytopenia, and granulocytosis. The observation of a possible tick bite lead to a tentative diagnosis of Rickettsiosis, and the patient received intravenous cefepime, clarithromycin, and linezolid, along with lactated Ringer's solution and dobutamine. 24 Although intensive care treatment was instituted, together with hemodialysis and inotropic and vasopressor therapy, the patient's condition degenerated rapidly with hemodynamic collapse and death on day 13 of her illness. No postmortem was conducted.

Patients 2 to 5 are described in detail elsewhere 24 and included 1 paramedic (patient 2) involved in the initial evacuation of the index case. Patient 2 was diagnosed with suspected thrombotic thrombocytopenic purpura, which was then changed to suspected viral haemorrhagic fever a day later, after the epidemiological link with patient 1 was made. 24 Patient 3 was an intensive-care-unit nurse that cared for the index case, and patient 4 was a cleaner who disinfected the room after the death of the index case. Patients 2 to 4 fell ill 9 to 13 days after probable exposure/contact with the index case, and all resulted in death. All 3 nosocomially transmitted patients were unwell for 10 to 13 days in the community before they were admitted and an epidemiological link with the index case established as well as VHF infection control measures implemented. Patient 3 was initiated on ribavirin on or around the same day that VHF was suspected in patient 2 (September 29 or 30, 2008). Patient 4 fell ill and sought care at her local clinic on September 27, but when seen as an outpatient at her local hospital 6 days later (3 days after the VHF alert and contact tracing commenced), she was initiated on therapy for tuberculosis (TB). She was admitted 2 days later, at which point the contact tracing team made contact with her, and she was referred to the teaching hospital for treatment.

Patient 5 was a 47-year-old white female who also worked in the intensive care unit and had contact with patient 2 (but not with the index case), just 2 days before the VHF alert was raised. There were noted lapses in personal protection, but fortunately by the time she fell ill she was known to the contact tracing team, and ribavirin was administered on day 2 of her illness based on suspected VHF. After being given ribavirin, patient 5 became seriously ill needing mechanical ventilation, but gradually recovered and was discharged after 42 days in hospital. She suffered prolonged neurological sequelae for up to 6 months after discharge from hospital. 24 The clinical presentation and course of Lujo VHF was quite consistent across all 4 fatal patients, starting with myalgia, headache, and fever, followed by onset of rash and pharyngitis on days 4 and 5.

Vomiting and diarrhea were present from days 3 to 7, and then the condition deteriorated with thrombocytopenia and elevated transaminases, severe neurological symptoms, hemodynamic collapse, and death. 24 Patient 5 received many of the same treatments as patients 1 to 4, with the key differences that might have contributed to her survival being prompt initiation of treatment with ribavirin, recombinant factor VIIa, N-acetylcysteine, and atorvastatin. 24 

The family Arenaviridae consists of 2 genera, Mammarenavirus and Reptarenavirus, which infect mammals and reptiles, respectively. 25 Arenavirus particles are enveloped and spherical in shape and possess a bisegmented single-stranded ambisense RNA genome comprising a large (L) and small (S) RNA segment, each contained within its own helical nucleocapsid. 26 Epidemiologically, the assumption is that these viruses are generally well adapted to their rodent hosts, and those that might be pathogenic in humans cause only mild febrile illness, otherwise more arenaviruses would have been previously discovered. NW arenaviruses appear to be more commonly associated with human disease, possibly influenced by the use of different receptors 28 : OW arenaviruses such as Lassa fever virus use α-dystroglycan (αDG) as a cellular receptor, which may be highly prevalent in the membranes of monocytes and dendritic cells, 29 but the natural ligand of αDG, laminin, does not prevent virus infection in vitro and other candidate receptors (Axl, Tyro3, LSECtin and DC-SIGN), including some shared with Ebola, have been shown in vitro to facilitate cell entry. 30 The primary receptor for NW arenaviruses is transferin receptor 1 (TfR1), which is widely distributed and would facilitate a broad cell tropism, 31 and there is in vitro evidence that even a single mutation can confer tropism to human cells. 32 

There have been 2 studies aimed at finding the natural animal host of LUJV and to more broadly investigate the prevalence and molecular epidemiology of arenaviruses in rodents and small mammals in Zambia. 33, 34 Combining data from both studies, arenaviruses were 

For other segmented RNA viruses, most notably influenza virus and SARS-CoV (severe acute respiratory syndrome coronavirus), reassortment and/or recombination are central to their importance as human pathogens, giving rise to the sudden emergence of novel species of global pandemic potential. There has hence been great concern that arenaviruses, with their established capacity to cause severe disease in humans, and their segmented RNA genomes could also give rise to novel species with pandemic potential. Recombinant mammarenaviruses have been produced in the laboratory for vaccine development purposes, 36, 37 and reptarenaviruses are highly recombinant (due to the pet trade and the housing of diverse snake species in close proximity), 38 but for wild-type mammarenaviruses with their segmented genomes and overlapping host species, the evidence for reassorted or recombinant species of either NW or OW mammarenaviruses is weak. 39, 40 The variable position of some OW arenaviruses on different branches, depending on which viral protein is analyzed, is suggestive of possible historical recombination events, but the branch lengths ( Figure 2 ) and sequence identities ( Table 2) suggest these events have been followed by significant divergence. When analyzing only a tiny fraction of the total number of quasi species in existence, more conserved regions might masquerade as evidence of recombination using some analysis tools. 39 As indicated in Table 2, the viral nucleoprotein appears to be more conserved than the other 3 viral proteins.

Phylogenetically LUJV is interesting, because amino acid identities show it is clearly among the OW arenaviruses, phylogenetic trees of amino acid sequences for all 4 viral proteins, consistently suggest that LUJV is the closest OW relative of the NW arenaviruses ( Figure 2 ). All 

The index case had regular contact with animals because she kept dogs, cats, and horses at her premises, and the outbreak response team found evidence of rodents, the natural host of all known arenaviruses, 23 around the stables. Patient 1 reportedly cut her shin on a broken bottle on August 30, 3 days before she became ill, 23 and it is plausible that the wound came into contact with rodent feces/ urine, but in Lusaka, whether on peri-urban farms or in crowded townships, people are in close contact with rodents, and if the natural host is a common rodent species, it begs the question of why LUJV infections are not more common in humans? Taken together with previous surveillance studies that did not detect LUJV in 420 wild-captured rodents, 33, 34 it seems plausible to speculate that a rare and unlikely transmission event led to the infection of a human by LUJV. The environment around the farm would support other small mammal species (rabbits, genets, civets, etc.), but as arenaviruses seem to have to occur in the late stages of the infection, maybe during the last 3 days before death, 24 a likely smaller window of transmission compared with EVD. 44 While the 2008 outbreak did not spread to urban populations, in a possible future scenario, an infected individual could travel to crowded urban centers, dramatically increasing the risk of uncontainable spread. At the private hospital involved in the LUJV outbreak, the level of awareness for possible VHF was low, 24 and without intervention this is likely also to be the case at over-crowded government clinics that serve poor communities in Lusaka. Health-seeking behavior may involve visiting traditional healers that would also delay diagnosis, as documented in West Africa during the recent EVD epidemic. 45 Zambia's high burden of human immunodeficiency virus/TB, malnutrition, and other diseases of poverty could also impact on the size and impact of a future outbreak. Taking all these factors into consideration, it would be dangerously complacent to think that the magnitude and spread of a potential future LUJV outbreak will be similar to that of 2008. 

Diseases of the central nervous system caused by lymphocytic choriomeningitis virus and other arenaviruses

CDC: Viral Hemorrhagic Fevers Fact Sheet. Branch SP

Detecting the emergence of novel, zoonotic viruses pathogenic to humans

Ebola Outbreaks

Ecologic and geographic distribution of filovirus disease

Will Africa's future epidemic ride on forgotten lessons from the Ebola epidemic

Ebola failures prompt WHO rethink

A retrospective and prospective analysis of the west African Ebola virus disease epidemic: robust national health systems at the foundation and an empowered WHO at the apex

The chronology of the international response to Ebola in western Africa: lights and shadows in a frame of conflicting position and figures

Ebola: missed opportunities for Europe-Africa research

Ebola RNA persistence in Semen of Ebola virus disease survivors-preliminary report

Persistence and genetic stability of Ebola virus during the outbreak in Kikwit, Democratic Republic of the Congo

Thousands of Ebola survivors experience serious medical complications

Ebola control: effect of asymptomatic infection and acquired immunity

Human asymptomatic Ebola infection and strong inflammatory response

Undiagnosed acute viral febrile illnesses

Seroepidemiological study reveals regional co-occurrence of Lassa-and Hantavirus antibodies in Upper Guinea, West Africa

High seroprevalence of Rift Valley fever and evidence for endemic circulation in Mbeya region, Tanzania, in a cross-sectional study

Interepidemic Rift Valley fever virus seropositivity, northeastern Kenya

Ebola haemorrhagic fever in Zaire

Nosocomial outbreak of novel arenavirus infection, southern Africa

Clinical features and patient management of Lujo hemorrhagic fever

Past, present, and future of arenavirus taxonomy

Arenaviridae. In: ICTVdB-The Universal Virus Database, version 3

Gairo virus, a novel arenavirus of the widespread Mastomys natalensis: genetically divergent, but ecologically similar to Lassa and Morogoro viruses

Comparative analysis of disease pathogenesis and molecular mechanisms of New World and Old World arenavirus infections

Immunosuppression and resultant viral persistence by specific viral targeting of dendritic cells

Identification of cell surface molecules involved in dystroglycan-independent Lassa virus cell entry

Transferrin receptor 1 is a cellular receptor for New World haemorrhagic fever arenaviruses

Host-species transferrin receptor 1 orthologs are cellular receptors for nonpathogenic new world clade B arenaviruses

Novel arenavirus, Zambia. Emerg Infect Dis

Molecular surveillance and phylogenetic analysis of Old World arenaviruses in Zambia

Genetic detection and characterization of Lujo virus, a new hemorrhagic fever-associated arenavirus from southern Africa

Generation of recombinant arenavirus for vaccine development in FDAapproved Vero cells

Machupo virus expressing GPC of the candid#1 vaccine strain of junín virus is highly attenuated and immunogenic

Widespread recombination, reassortment, and transmission of unbalanced compound viral genotypes in natural arenavirus infections

Arenavirus genetic diversity and its biological implications

Lassa virus isolates from Mali and the Ivory Coast represent an emerging fifth lineage

Isolation of Tacaribe virus, a Caribbean arenavirus, from host-seeking Amblyomma americanum ticks in Florida

Rapid spread of Zika virus in the Americas-implications for public health preparedness for mass gatherings at the 2016 Brazil Olympic Games

Divergent viruses discovered in arthropods and vertebrates revise the evolutionary history of the flaviviridae and related viruses

Temporal and spatial analysis of the 2014-2015 Ebola virus outbreak in West Africa

The impact of traditional and religious practices on the spread of Ebola in West Africa: time for a strategic shift

Risk assessment for Yellow fever in western and north-western provinces of Zambia

Potential mammalian filovirus reservoirs

Viral hemorrhagic fever diagnostics

WHO: How to safely collect blood samples by phlebotomy from patients suspected to be infected with Ebola. WHO: Geneva, 2016. 51. WHO: Emergency guidance-selection and use of Ebola in vitro diagnostic (IVD) assays

Detection of all known filovirus species by reverse transcription-polymerase chain reaction using a primer set specific for the viral nucleoprotein gene

Real-time, portable genome sequencing for Ebola surveillance

Tacaribe virus causes fatal infection of an ostensible reservoir host, the Jamaican fruit bat

Lujo viral hemorrhagic fever: considering diagnostic capacity and preparedness in the wake of recent Ebola and Zika virus outbreaks